About Ikonisys S.A.

Company Description

Ikonisys is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing their disease.

Through its breakthrough fluorescence microscopy platform, Ikonisys continues to develop a stream of oncology tests for a variety of cancers. At the center of the platform is the Ikoniscope20®, a robotic, high-throughput, microscopy system that provides a true “walk away” automated solution. In addition to providing high quality cell images, the platform analyzes the cells of interest, offering an interpretation of the analysis, to facilitate the quick, accurate reporting of the test result.

Year founded

1999

Headquarters

62 Rue de Caumartin, 75009 Paris – France

Shareholder information

Shares outstanding

9,481,727

IPO

July 19, 2021

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.